Ultravana® Healthcare Professional Training
What is Ultravana® Period Pain Relief 250 mg Gastro-resistantTablets ?
Ultravana is a pharmacy-only treatment for the relief of dysmenorhoea (period pain)6 in women aged 15 to 50 years.3 Ultravana contains the NSAID naproxen 250mg (in a gastro resistant tablet), recommended by NICE as a first-line analgesic for dysmenorrhoea.1 With the prevalence of period pain as high as 71% in women of reproductive age¹ the launch of Ultravana Period Pain Relief provides an opportunity for pharmacy to support their patient’s pain management with a long-lasting treatment option4,5,6.
The overall aim of this training is to support you in conducting effective, patient-specific, clinical consultations on period pain, and enable you to appropriately supply Ultravana Period Pain Relief 250mg gastro-resistant tablets (naproxen), available without prescription from pharmacies to women who are eligible.
Learning Objectives
- To understand the definition, symptoms and causes of primary and secondary dysmenorrhoea
- To be aware of the impact dysmenorrhoea has on a patient’s quality of life
- To recognise which dysmenorrhoea symptoms, require referral
- To know how to manage dysmenorrhoea with recommended over-the-counter (OTC) treatments
- To understand the mode of action of Ultravana in dysmenorrhoea
- To be able to recommend Ultravana appropriately
- To be able to offer appropriate advice on the use of Ultravana in dysmenorrhoea.
Ultravana® Training Materials
Access Ultravana training materials online or download the hard copies for your convenience (including our pharmacist training guide, patient information leaflet, summary of product characteristics and optional checklist).
-
Essential Information
Ultravana® Period Pain Relief 250mg Gastro-resistant tablets (Naproxen) PL 20075/0619. Indication: Treatment of primary dysmenorrhoea in women aged 15-50 years. Posology: Day one: two tablets (500mg) to be taken, followed by one tablet (250mg) every 6-8 hours, if needed. Days 2 and 3: one tablet (250mg) to be taken every 6-8 hours. Maximum daily dose of 3 tablets (750mg), for a maximum of 3 days continuous use in any one cycle. Contraindications: hypersensitivity to the active substance or any of the excipients, patients with a history of, or active peptic ulcers and active gastrointestinal (GI) bleeding, history of GI bleeding or perforation related to previous NSAID therapy, aspirin or NSAID sensitivity, patients with severe heart, hepatic or renal failure, or those in the third trimester of pregnancy. Precautions: Not recommended in the elderly, in the first 6 months of pregnancy, when breast-feeding or in women attempting to conceive. Caution in patients with bronchial asthma or allergic disease, cardiac impairment, hypertension, impaired renal function, liver dysfunction, peripheral arterial or cerebrovascular disease, history of GI disease (e.g., ulcerative colitis, Crohn’s disease), coagulation disorders, and those taking oral corticosteroids, anticoagulants, antiplatelet agents, SSRIs or other NSAIDs. Contains lactose, not for patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. Side effects: Hypersensitivity reactions including non-specific allergic reactions and anaphylaxis, respiratory tract reactivity e.g., asthma, bronchospasm, dyspnoea, various skin reactions e.g., pruritus, urticaria, purpura, angioedema, bullous reactions including epidermal necrolysis, erythema multiforme, Stevens-Johnson Syndrome, DRESS. GI ulceration or haemorrhage, peptic ulceration, or perforation., hyperkalaemia, cardiac and congestive heart failure, myocardial infarction, stroke, renal failure, jaundice, hepatitis, meningitis. MA Holder: Accord Healthcare Limited, Sage House, 319 Pinner Road, HA1 4HF, UK. Classification: P. RRP: 9 tablets £5.95. Date: August 2024. For full information see the Ultravana SPC.